Characteristic behavioral anomalies in rats prenatally exposed to 5-bromo-2'-deoxyuridine.
The aim of the present study was to characterize behavioral anomalies in rats prenatally exposed to 5-bromo-2'-deoxyuridine, a useful model of hyperactive disorder. Rats were treated with BrdU at 50mg/kg IP or carboxymethylcellulose, its vehicle, on gestational Days 9 through 15, and their offsprings were subjected to behavioral tests. Rats prenatally exposed to 5-bromo-2'-deoxyuridine showed higher locomotor activity levels when the lights were turned off, and these levels kept increasing throughout the dark cycle. In an elevated plus maze, the rats prenatally exposed to 5-bromo-2'-deoxyuridine exhibited decreased anxiety-related behavior, including higher open arm entries and a longer time spent per one open arm entry when compared with rats prenatally exposed to carboxymethylcellulose. Methylphenidate, a psychostimulant that suppresses hyperactivity in humans with attention-deficit hyperactivity disorder, increased locomotor activity in both rats, with a greater sensitivity in rats prenatally exposed to 5-bromo-2'-deoxyuridine. Desipramine, a specific noradrenaline uptake inhibitor, normalized the hyperactivity of rats prenatally exposed to 5-bromo-2'-deoxyuridine. Paroxetine, a selective serotonin reuptake inhibitor, also normalized the hyperactivity and the low anxiety-related behavior in the elevated plus maze. These results suggest that rats prenatally exposed to 5-bromo-2'-deoxyuridine are hyperactive and exhibit a lower anxiety level. Dysfunctional monoaminergic neurons may be, at least in part, the cause of the behavioral anomalies.
Orito
Kensuke
K
Department of Pharmacology, Azabu University School of Veterinary Medicine, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 229-8501, Japan. oritok@azabu-u.ac.jp
Morishima
Akihiko
A
Ogawa
Tetsuo
T
Muneoka
Katsumasa
K
Kuwagata
Makiko
M
Takata
Jiro
J
Mishima
Kenichi
K
Fujiwara
Michihiro
M
D000818:Animals; D000831:Animals, Newborn; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D000963:Antimetabolites / Q000633:toxicity; D001008:Anxiety Disorders / Q000139:chemically induced / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D015306:Biogenic Monoamines / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000254:growth & development* / Q000503:physiopathology; D001973:Bromodeoxyuridine / Q000633:toxicity*; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D001523:Mental Disorders / Q000139:chemically induced* / Q000151:congenital / Q000503:physiopathology; D009043:Motor Activity / Q000187:drug effects; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
D000929:Antidepressive Agents, Tricyclic; D000963:Antimetabolites; D015306:Biogenic Monoamines; D001973:Bromodeoxyuridine; D000697:Central Nervous System Stimulants; D017367:Selective Serotonin Reuptake Inhibitors